To The Moon

$Moderna, Inc.(MRNA)$ just showed how explosive a successful cancer-vaccine catalyst can be.

A $1,000 overnight options bet reportedly turned into more than $7.3M after Moderna announced a major Phase 3 win for its personalized cancer vaccine program.

But here's the catch:

This is an extremely high-risk game.

Two cancer-vaccine Phase 3 programs have already failed in 2026, including $IOBT, which filed for Chapter 7 after missing its primary endpoint, and $IMMP, which discontinued its Phase 3 program for futility.

So the next wave of catalysts could create massive winners — or wipe out years of work.

Here are 5 biotech names with major clinical readouts ahead:

1. $CG Oncology Inc.(CGON)$

Oncolytic virus delivered directly into the bladder for intermediate-risk bladder cancer.

PIVOT-006: Topline data guided for the near term.
BLA completion: Q4 2026

2. $Summit Therapeutics PLC(SMMT)$

Bispecific antibody targeting PD-1 + VEGF in first-line lung cancer.

HARMONi-3: Final PFS + interim OS expected in 2H 2026.
PDUFA: Nov. 14, 2026

3. $BriaCell Therapeutics Corp.(BCTX)$

Off-the-shelf cell-based vaccine combined with a checkpoint inhibitor for metastatic breast cancer.

Bria-ABC: Interim OS data expected after 144 events.
Topline: 2026
Fast Track designation

This one is a micro-cap, which also means the risk — and potential volatility — is much higher.

4. $Greenwich Lifesciences Inc(GLSI)$

HER2 peptide vaccine designed to prevent recurrence following surgery in breast cancer patients.

FLAMINGO-01: Event-driven interim analyses at 28 and 56 events.
Target HR: 0.55

5. $Immunocore Holdings plc(IMCR)$

T-cell engager targeting gp100 in previously treated advanced cutaneous melanoma.

TEBE-AM: Enrollment completed in 1H 2026.
Topline: Potentially as early as 2H 2026

Same tumor type being studied in INTerpath-001.

⚠️ The important part

$MRNA's success doesn't make these five the "next MRNA."

It shows just how much upside exists when a cancer vaccine or immunotherapy finally produces convincing late-stage data.

But the failure rate is brutal.

$IO Biotech, Inc.(IOBT)$ → Chapter 7
$Immutep Limited(IMMP)$ → Phase 3 stopped for futility

And that's the point:

This is not a basket of guaranteed winners.

It's a basket of binary clinical catalysts.

One positive Phase 3 result can completely reset a company's valuation.

One failed endpoint can do the opposite.

Huge upside. Huge downside.

Size accordingly. 🎯